In a new job - March 25, 2021
Ferring appoints Jan Lundberg to its Group Board
Ferring Pharmaceuticals has announced that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson. “I am delighted to welcome Jan to the Ferring Group Board and am confident that, with his strong scientific […]
Collaboration - October 21, 2016
North Zealand University Hosiptal, Ferring collaborate
Ferring Pharmaceuticals and North Zealand University Hospital (Nordsjællands Hospital) have formally inaugurated a multi-year collaboration aimed at transforming the way in which patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) manage their condition and receive medical care. During the event, held at North Zealand University Hospital in Copenhagen, local doctors, researchers and IBD […]
Collaboration - January 27, 2016
Ferring and Karolinska Institutet collaborates
Ferring Pharmaceuticals and Karolinska Institutet have entered a collaboration agreement for the establishment of a research center exploiting the human microbiome. The programme will be fully funded by Ferring Pharmaceuticals and governed by a joint steering committee. The proposed project focuses on therapeutic areas where Ferring has extensive expertise. Karolinska Institutet has a deep understanding of […]
Drug Development Pharma - October 24, 2013
Ferring’s Misodel approved for labour induction
Ferring Pharmaceuticals have announced that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction has successfully completed the European Decentralised Procedure. MISODELTM has been approved for induction of labour in women with an unfavourable cervix, from 36 weeks of gestation, in whom induction is clinically indicated. An unfavourable cervix is a cervix that […]
